Trial Profile
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Peptide hydrolase inhibitors (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 09 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Oct 2014 New trial record